1. Net debt-to-EBITDA ceiling of 3x-3.5x for acquisitions On track - At the Q1 FY27 call, management said they would not want to be above 3x or 3.5x net debt-to-EBITDA for whatever acquisition opportunity they consider. Q1 FY27 net debt to EBITDA stands at 2.07, and Q4 FY26 was at 2.3x, both below the stated ceiling.
2. Base business EBITDA margin - at least 0.5% improvement per year On track - At the Q1 FY27 call, management reiterated the standing guidance of at least 0.5% EBITDA margin improvement per year for the base business, in place for the last 2 years. Q1 FY27 base business EBITDA margin was 33.3%, a 0.5% improvement vs 32.8% last year; Q4 FY26 base margins were 32.7%.
3. Base business gross margin - 77% sustainable On track - At the Q1 FY27 call, management said base business gross margin up to 77% is "definitely sustainable" vs 76-76.5% last year, with anything beyond depending on other factors. Q1 FY27 base business gross margin was close to 78%, helped by price increases, higher branded mix, and positive forex.
4. Curatio business - similar high growth trajectory for rest of FY27 On track - At the Q1 FY27 call, management said they are hopeful the Curatio business should continue with a similar high growth trajectory for the rest of the year, with further field force expansion this financial year. Curatio grew 34% in Q1 FY27, driven by OTC ad spends and field force expansion, after 27% growth in FY26.
5. JB integration - complete over next 2 to 3 quarters On track - At the Q1 FY27 call, management said integration activities are expected to be completed over the next 2 to 3 quarters, with a minor and transient revenue impact in some territories until then; they confirmed normalization of any transition impact by the end of this year. The merger completed 8th July 2026, brand transfers were implemented immediately in July, and combined field force stood at 9,400.
6. JB CDMO business - high single-digit to low double-digit CC growth in FY27 On track - At the Q1 FY27 call, management guided high single-digit to low double-digit constant currency growth for the JB CDMO business for full year FY27. JB international business including CDMO grew 12% in Q1 FY27; no separate CDMO figure was disclosed.
7. JB international business - recovery post changes in FY27 On track - At the Q1 FY27 call, management said JB's international business "should also recover post the changes implemented" in FY27. JB international business grew 12% in Q1 FY27.
8. JB India RX business - double-digit revenue growth in FY27 On track - At the Q1 FY27 call, management said for full year FY27, double-digit revenue growth for JB's India RX business "should still be possible" given robust underlying trends in Q1. JB India branded business grew 13% in Q1 FY27.
9. US new product launches - from April 2024, positive contribution over 3 years On track - In the FY24 annual report, management said US new product launches would start from April 2024 following USFDA approval of the Dahej and Bileshwarpura facilities, with the US expected to contribute positively over the next 3 years. FY26 saw the US generics business delivering growth on new launches, Q1 FY27 US revenues rose 23% in constant currency with 17 products launched in 30 months, and Q4 FY26 the US was profitable before R&D expenses.
10. Germany OTC business - increase share over next 3 years Pending - In the FY24 annual report, management said incremental investments were being made to increase the share of the OTC business in Germany over the next 3 years and to build a portfolio around a new customer segment. Q1 FY27 Germany revenues were down 9% in constant currency on supply disruption and lower tender uptake, with management saying "we are still in the middle of the woods"; no OTC share update was given.
11. Brazil generics - 60,000 points of sale and 8%+ market share Partial - In the FY24 annual report, Brazil aimed to expand its Generics business with the goal of enhancing reach to 60,000 points of sales and achieving over 8% market share. FY24 Gx products were available at 45,000 points of sale, with Gx business growth surpassing market expectations; no update on the 60,000 points or 8% share in later notes.
12. Brazil - six new products in existing business, incl. ADHD entry, in FY25 Partial - In the FY24 annual report, Brazil aimed to introduce six new products in its existing business during the year, including entry into the ADHD segment of CNS therapy. FY24 saw three products launched and a second sales team added for CNS products; no confirmation of the six FY25 launches appears in the notes.
13. JB Pharma acquisition - 46.39% stake at ₹1,600 per share Delivered - At the Q4 FY25 PPT, Torrent announced acquisition of 46.39% equity stake in JB Pharma via SPA at a consideration of ₹11,917 crores (₹1,600 per share), with a mandatory open offer at ₹1,639.18 per share and intent to acquire up to 2.80% from employees. The controlling stake acquisition completed in FY26, JB Pharma was consolidated from 21st January 2026, and the merger completed 8th July 2026.
14. Germany growth - low single-digit, below 5% in constant currency On track - At the Q4 FY26 call, management guided Germany to low single-digit growth for next year, below 5% in constant currency. Q1 FY27 Germany constant currency revenue of €2.9 crore was down 9%, impacted by supply disruption at third-party suppliers - a prominent supplier contributing about 10-15% of revenue has been out of business - and lower tender uptake.
15. Brazil growth - 10-15% top-line over FY26-27 On track - At the Q4 FY26 call, management guided to double-digit growth, 10% to 15% top-line growth over the course of FY26-27 with no quarterly guidance; in Q1 FY27 they expected normalized growth to return to mid-teens, saying Q1 constant currency sales would have grown 15-18% without the channel inventory correction. Q1 FY27 Brazil constant currency revenues of BRL 14.7 crore were up 3% YoY on internal sales amid a one-time channel inventory reduction, while IQVIA showed Torrent growing 19% vs market growth of 4%; Q4 FY26 constant currency revenue was up 11% YoY.
16. US business - single-digit growth, profitable before R&D On track - At the Q4 FY26 call, management said single-digit growth is a good way to look at the US for the next couple of years before a major own product launch, with the business profitable before R&D expenses - the stated objective - and work towards full-cost profitability; in Q1 FY27 they said the US would be a profitable entity this year, unlike the last 5 years. Q1 FY27 US constant currency revenues of $44 million were up 23%, driven by new launches and one-time opportunities, with 17 products launched in the last 30 months.
17. MR expansion - up to 7,500 reps in FY27 On track - At the Q4 FY26 call, management said the plan to go up to 7,500 reps in FY27 continues and will be executed as per plan, with no further expansion after JB MR strength merges; in Q1 FY27 they said total MR strength is expected to be closer to 9,000 from 9,400 as integration proceeds. Q1 FY27 combined field force stood at 9,400 (base 7,200, JB 2,200) with combined PCPM just over ₹10 lakhs; FY26 field force was 7,100 ex-JB, in line with the earlier indicated number.
18. Semaglutide oral gross margins - reach reasonably high level in 6-12 months Pending - At the Q4 FY26 call, management said Semaglutide oral gross margins are expected to reach a reasonably high level in the next maybe 6 to 12 months as API prices drop, with injectable Semaglutide following the normal trajectory to base-business gross margin levels and EBITDA margin reversal hopefully starting by next year. Q1 FY27 base business gross margin was close to 78% vs 76-76.5% last year, but no semaglutide-specific gross margin trajectory was disclosed.
19. Semaglutide India market share - maintain majority share On track - At the Q4 FY26 call, management said early-mover advantage is expected to help maintain majority market share despite a new oral competitor entering as of 21st May; in Q1 FY27 they said India market share should not change materially assuming supply and competition situations remain unchanged. Q1 FY27 semaglutide franchise recorded 36% combined share per PharmaTrack and held 94% share in the oral market in June, vs 38% among generic players, 28% injectable and 100% oral in Q4 FY26.
20. Semaglutide India first-year sales - ₹200-250 cr Partial - At the Q4 FY26 call, management indicated \~₹200 crore to 250 crore for Semaglutide first-year sales vs Sitagliptin's ₹70-75 crores first year; in Q1 FY27 they said the earlier ₹250 cr target is "definitely not going to be possible" given the supply issue, with a revised target after one more quarter. Q1 FY27 combined semaglutide sales were ₹50 crores, with the injectable supply issue affecting \~20% of total monthly contribution and all Samalex SKUs expected back by end of August.
21. India base business - mid-teens organic growth in FY27 On track - At the Q4 FY26 call, management confirmed mid-teens organic India growth for FY27 would be "realistic" absent external demand shocks, with the base business expected to keep outperforming market growth; in Q1 FY27 they said the trajectory should be similar to Q1's 19% as long as IPM growth continues and the semaglutide situation normalizes. Q1 FY27 base India business grew 19% vs IPM growth of 12%, and excluding semaglutide the India organic business grew roughly 16% vs a previous trajectory of \~12.5-13%.
22. JB Pharma revenue synergies - next two to three years On track - At the Q4 FY26 call, management said no material revenue synergies will be seen in FY27 because changes take time to implement, with the timeline remaining the next two to three years; in Q1 FY27 they said synergies will only be quantified starting next year (FY28) after full integration completes. Q1 FY27 Torrent with JB now ranks first in the cardiac market, combined field force stood at 9,400, and integration is expected to complete over the next 2 to 3 quarters; no synergy quantification yet.
23. JB Pharma cost synergies - ₹450 cr by year 3, 20-60-20 phasing On track - At the Q4 FY26 call, management guided up to ₹450 crores of JB Pharma cost synergies by year 3 with \~20% in year 1, 60-80% cumulative by year 2 and the last 20% in year 3 (FY27-FY29 phasing of 20-60-20); in Q1 FY27 they said the 3-year picture could be realized much faster since the merger closed \~6 months ahead, with the first-year ₹90 cr target tracking ahead - "if it's going to be above 90, it's definitely going to be above 100". Q1 FY27 cost synergies are being implemented sooner than expected, and JB underlying business Q1 EBITDA margin improved more than 6% to 35.3%; no quantified full-year number disclosed yet.
24. Resmetirom (NASH) India launch - next 12 to 18 months On track - At the Q4 FY26 call, management said the Resmetirom (NASH) India launch would come after patent expiration within the next year, in the next 12 to 18 months, with the exact timeline not shareable then. Q1 FY27 the Phase 3 clinical trial for Resmetirom is underway, with no innovator present in India and the opportunity projected to be large-sized; no launch date update was given.
25. India first-to-market launches - minimum 1-2% incremental India growth Pending - At the Q4 FY26 call, management said any new first-to-market launch, such as Resmetirom/NASH, is expected to add incrementally minimum 1% to 2% to total India growth over the first year or two of launch. Q1 FY27 Torrent first launched generic Brexpiprazole in India in April after conducting clinical trials, with a good start in CNS/psychiatry as a moderate-sized opportunity, and the Resmetirom Phase 3 trial is underway; no launch-year growth contribution has been quantified yet.
26. Germany biosimilars - participate in tenders from June-July 2026 On track - At the Q4 FY26 call, management said Torrent will start participating in biosimilar tenders in the coming months, with first tenders expected in the June-July timeframe, and is open to partnerships around the world including Asian partners. The first biosimilar was launched in Germany in Q4 FY26 via a European partner with sales not yet material, and a German regulatory change for automatic substitution and tender inclusion took effect April 2026; no specific tender participation update appeared in Q1 FY27 notes.
27. Semaglutide other markets - filed in 4-5 markets, Wave 1 launches Pending - At the Q4 FY26 call, management said Torrent filed Ozempic in about four-five markets where it would be in Wave 1 of launches, sometimes first to market, with no volume guidance given for FY27-29. No update on other-market semaglutide filings appeared in Q1 FY27 notes.
28. Brazil Semaglutide - Ozempic filing under ANVISA review Partial - At the Q4 FY26 call, management said Torrent's Ozempic file is under ANVISA review with expectations of being amongst the first five players, and Wegovy not yet filed in Brazil but being worked towards; in Q1 FY27 they said the Brazil semaglutide filing will take "months and not years". Q1 FY27 the filing is still with the regulator, which has expedited semaglutide approvals with 5 coming through recently, and Torrent has not launched in Brazil yet, admitting the first-mover advantage is lost; no suitable distributor-type partner has been found.
29. JB sales-force attrition - reach Torrent base level by next year On track - At the Q4 FY26 call, management said JB sales-force attrition was below industry average in April but still far from Torrent base business attrition of high single-digit, expected to reach that level by next year. Q1 FY27 JB field force attrition was down to 16% in June compared to nearly 30% pre-acquisition.
30. R&D spend - \~5.5% of sales in FY27 Pending - At the Q4 FY26 call, management said R&D spend was \~5% of sales in FY26, with incremental \~0.5% expected in the upcoming year (FY27), largely going to India and US. No specific R&D spend disclosure for Q1 FY27 appears in the notes.
31. Brazil launches - two products per team per year Pending - At the Q4 FY26 call, management said Brazil has three launch teams, ideally about two products per team per year. Q1 FY27 58 molecules are awaiting ANVISA approval with no specific launch count disclosed, and Q4 FY26 saw the first oncology product launched in Brazil.
32. Net leverage - below 1.0x over next two years (Ind-Ra expectation) Delivered - In the FY22 announcement, Ind-Ra expected net leverage ratios to decline below 1.0x over the next two years, with lower capex intensity of ₹2.5 billion-300 crore FY22-FY24. Net leverage was around 1x at FYE22, Net Debt/EBITDA reached 0.9x in FY24 and 0.6x in FY25, before rising to 2.3x in FY26 following the JB Pharma acquisition and 2.07 in Q1 FY27.
33. Brazil - entry into newer therapeutic segments starting early 2023 Delivered - In the FY22 annual report, Brazil operations were preparing for entry into newer therapeutic segments starting early 2023. FY24 saw Brazil launch three products, add a second sales team for CNS products with a field force of around 321, and Q4 FY26 the first oncology product was launched in Brazil.
34. Field force PCPM productivity - ₹10 lakhs Delivered - In the FY21 annual report, the Company set a goal of achieving field force PCPM productivity of ₹10 lakhs, nearly double the industry average. PCPM improved from under ₹5 lakhs in 2017-18 to crossing ₹8 lakhs in 2020-21, field force productivity reached over ₹1.2 crore/MR during FYE22 from ₹7.6 crore/MR annually in FY18, and Q1 FY27 combined PCPM was just over ₹10 lakhs.
35. Field force expansion - sizeable expansion over next two to three years Delivered - In the FY21 annual report, a sizeable expansion of the field force was planned over the next two to three years in certain therapies as the Company enters more high-potential markets and launches new products. MR strength grew from \~5,500 in FY23 to \~5,700 in FY24, \~6,400 in FY25 and \~7,000 in FY26, reaching 9,400 combined in Q1 FY27.
36. Oncology greenfield facility - commercialise within two years from FY23 Delivered - In the FY23 annual report, the oncology greenfield facility in Gujarat was expected to start commercialising products within the next two years, with the site awaiting approvals for in-house developed products in European and US markets. FY23 the facility obtained European Authority certification and passed the FDA audit; FY24 the Bileshwarpura facility received USFDA clearance and commenced commercial operations with the first oncology product launched from it; FY25 the dedicated oncology facility received FDA approval and the first oncology drug was launched in the US.
37. Germany generics market coverage - 65% over near to medium term Partial - In the FY23 annual report, the target was to increase coverage of the German generics market to 65% over the near to medium term, from around 55% at the time. FY26 the portfolio covered 56% of the overall German generics market, with management expecting coverage to expand in coming years; the Germany business declined due to disruptions at third-party suppliers and Q1 FY27 revenues were down 9% in constant currency.
38. Curatio acquisition - 100% stake, top 5 in derma Delivered - At the Q1 FY23 PPT, Torrent announced the acquisition of 100% of Curatio Health Care, with Torrent to enter the top 5 corporates amongst dermatologists. The acquisition completed in October 2022, NCLT Ahmedabad approved the amalgamation scheme on 17 May 2023 with entry into the top-ten dermatology players at rank 7, and the business has kept growing - surpassing expectations in FY25 with high double-digit growth and 27% growth in FY26.
39. Omzotirome (NCE for diabetes) - Phase-3 trial, India first to launch Pending - In the FY21 annual report, Omzotirome (NCE for diabetes) was undergoing a pivotal Phase-3 clinical trial in key markets, with India gearing up to be the first to launch. No update on Omzotirome appears in later notes.